Time: 9:00 AM to 6:00 PM
Venue: Four Points By Sheraton San Diego Downtown
**Please note the registration will be closed 2 days (48 Hours) prior to the date of the seminar.
Understanding basic clinical research requires excellent people and project management skills, and very good scientific writing and organization skills. Also paramount is gathering necessary information to manage the statistical analysis and data management of all the many clinical studies. The clinical development plans must be laid by experienced leaders and project managers. The clinical plan includes the budgets and timeline necessary to properly research the drug and advance it through all the testing necessary to achieve approval by FDA. The various phases of drug development (Phases I-IV) are necessary for most new chemical entities. Protocols are required for all clinical tests and this usually starts with a literature review, establishing key efficacy and safety parameters and determining proper sample size. Sample size calculations are a very important aspect of clinical trials, as are the data collection forms, therefore the statistics and data management departments must be included for their input into the protocol and timelines. An initial input, draft review and final protocol review meetings of all concerned departments should also include labeling, manufacturing, regulatory, legal, project management. It is also a good idea to get individual investigators input into the protocol design and data collection forms. At this point they can also create a draft budget for their participation. Once all input has been gathered the sponsor approval process can proceed. Once the sponsor has approved the protocol, all relevant IRBs are asked by their investigators to approve the protocol. The FDA must be sent a copy of the protocol and if critical feedback isn't received in 30 days, the study can go forward. Writing a single protocol can take a month or more.
Once a clinical and project plan is developed, protocols are created and approved, everyone must be trained. This can take days or many weeks depending on experience and expertise. The final package required for a good solid monitoring team to follow, should consist of approved protocol and consent, data collection forms, listing of all intended principle investigators and contacts, all necessary IRB information. Excellent tracking and communications is imperative. All communication with investigator sites must be documented, as all communications with IRBs and FDA. Generally speaking the monitor is the focus for each site unless problems arise that require sponsor scientific or medical input.
Monitoring must be performed and 100% data checking done unless other arrangements have been made and agreed upon. My preferences are for 100% data checking, and it is very important for first time in man studies. All adverse events must be tracked on the case report forms for each patient and all serious adverse events and deaths must be tracked on the patients case report forms as well as tracked separately. The sites are not expected to communicate with the FDA for routine study management. Only if very serious unresolved persistent study management problems, adverse events or deaths occur, does the site communicate with FDA. The sponsor must be informed prior to any communication with the FDA.
The best outcomes are usually tied to a well-constructed clinical and project plans with excellent protocols and detailed budgets. Most ethical pharmaceutical companies also insist on complete honesty in all aspects of their research. CRAs and monitors must be included as the focus point for budget negotiations and investigator payments. This necessitates the determination of evaluable and non- evaluable patients prior to payments. The best laid plans do not ensure drug safety and efficacy; however no new medications can possibly make it without them.
This seminar should be attended to ensure the proper compliance and development of traditional and new cardiovascular medications. Failure to attend could result in poorly managed clinical trials, wasted financial resources and liability based law suits. The development of well-designed clinical trials and rigorous monitoring is required. From the literature review to the last appendix a complete understanding of regulations pertaining to clinical research and monitoring a well-designed protocol is necessary. All project managers know that the critical path thru clinical research is extremely tightly regulated and fraught with pitfalls. Financing by the sponsor/developer of the drug is highly scrutinized for value and good management. Monitoring according to Good Clinical Practice guidelines is required to determine evaluable patients. The more mistakes that are made the higher the cost. It takes 10 times as much time and money to fix mistakes/errors and misunderstandings as it does to do it right from the beginning. It requires significant training, resources and extraordinary diligence, planning and execution to achieve successes in cardiovascular clinical research.
Driving the clinical development, protocols and subsequent monitoring on the project requires increasing knowledge about any drug under development. It must be thoroughly and completely understood, down to the last comma. Similarly the accompanying monitoring of all the protocols, must be completed in an efficient, most forth right manner, to ensure viable data and statistical analysis. The documentation of these efforts by not only the sponsor but by all investigators and staff involved is tremendous. Training of all individuals and monitors must be flawless yet very efficient since this is a very competitive field. In addition, the IRBs and FDA will expect nothing short of perfection.
Clear direction and excellent communication are required to achieve the approval of these new cardiovascular drugs. The proper balance of pushing forward and yet addressing all safety considerations is paramount. Many bottlenecks can be prevented by a determined project manager and medical director who understand how to manage people and projects. Honest assessments of costs in development and monitoring are important to reach the market and significantly improve health and successfully obtain a good return on investment.
Protocols and Monitoring
Medical and Statistical (Evaluable patients)
Reviews and Meetings
Discussions and Q and A
|1||2 Attendees||10% off|
|2||3 to 6 Attendees||20% off|
|3||7 to 10 Attendees||25% off|
|4||10+ Attendees||30% off|
To avail the above group discounts, all the participants should register by making a single payment
Call our representative TODAY on 1800 447 9407 to have your seats confirmed!
Charlene M. Jett lives in Vandalia Illinois about 70 miles east of St. Louis. She is a scientist, clinical researcher, consultant, adventurer, volunteer, daughter of Charles W. and Sybel Harre. Charlene is well educated and has a Master's of Science in Management (1990) from Lake Forest Graduate School of Management, Lake Forest Illinois, a Master's of Science in Biology (1980) from Northeastern Illinois University, Chicago, Illinois and a Bachelor's of Science in Physiology (1972) from University of Illinois, Champaign-Urbana, Illinois.
Charlene is the founder, president and principal consultant of 3R's Management Consulting and Therapeutics Inc., and (1988-present). She has experience and expertise in Alzheimer's, dementia and memory problems. She has knowledge and experience in cardiovascular diseases and treatments and clinical trials. She has experience as a project manager for a fluoroquinolone antibiotic in aquaculture. She has been involved in regulatory reviews, scientific discovery and invention. She was a consultant for U.S. Army (twice) and the American Red Cross, with management level responsibilities. Charlene is experienced in making presentations, writing publications and reports, teaching and training. She taught graduate statistics and undergraduate ethics at National Louis University west of Chicago in 1991.
Charlene worked at Abbott Labs, Abbott Park (1980-1988) as a clinical researcher, sr. clinical researcher and project manager. She was a key scientist experienced in cardiovascular diseases treatment and was involved in the clinical development of Hyrin and Cartrol and their subsequent approval by FDA for treatment of high blood pressure. She is an experienced clinical protocol writer, monitor, and auditor. Charlene is experienced with anesthesia, (Etomidate) and medical devices for heart disease (stents, valves and catheters) in addition to pulse oximetry and blood pressure. Charlene has authored numerous scientific reports and protocols, and has traveled extensively in the US and abroad. She has also worked internationally in 3 different countries.
G.D. Searle/Monsanto/Pharmacia (1972-1980) Charlene was a research biochemist and sr. research biochemist working at the bench. She developed new biochemical and radiological enzyme assays on the rate limiting enzymes in the synthesis of progesterone and cholesterol. She authored numerous scientific reports and made several presentations. Charlene designed innumerable scientific experiments to test new chemicals in assays developed to predict their effects in human.
Charlene graduated from the University of Illinois (1970-1972) where she was a research technician and assistant in the physiology and agronomy departments. She developed enzyme assays for fish catalase and assays for detecting heavy metals by atomic adsorption in plant extracts.
Charlene is a member of Sigma Xi (past president of Abbott Chapter, 1987-1988), member of American Chemical Society (1988-present) and University of Illinois Alumni Association (life).
Charlene's achievements include invention of various drugs/chemicals, medical devices, diagnostics and other medical and defensive products. A listing of over 35 publications and presentations is available upon request.